losartan has been researched along with Encapsulating Peritoneal Sclerosis in 1 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, J | 1 |
| Jiang, Z | 1 |
| Zhang, H | 1 |
| Zhu, H | 1 |
| Zhou, SF | 1 |
| Yu, X | 1 |
1 other study available for losartan and Encapsulating Peritoneal Sclerosis
| Article | Year |
|---|---|
NADPH oxidase-dependent formation of reactive oxygen species contributes to angiotensin II-induced epithelial-mesenchymal transition in rat peritoneal mesothelial cells.
Topics: Actins; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Cadheri | 2011 |